Serum transforming growth factor-beta 1 is not a robust biomarker of incident and progressive radiographic osteoarthritis at the hip and knee: the Johnston County Osteoarthritis Project

Purpose To test whether serum transforming growth factor-beta 1 (TGF-beta 1) predicts incident and progressive hip or knee radiographic OA (rOA) Methods Serum TGF-beta 1 was measured for 330 participants aged 45 years and older in the Johnston County Osteoarthritis Project, with paired longitudinal films available for 618 hips and 658 knees Incident and progressive rOA were defined using Kellgren-Lawrence (K L) grade as well as osteophyte (OST) and joint space narrowing (JSN) scores Natural logarithm transformation was used to produce near-normal distributions for continuous TGF-beta 1 (lnTGF-beta 1) Separate multivariable Weibull regression models were used to provide hazard ratios (HRs) lot a 1-unit increase InTGF-beta 1 with each rOA outcome, accounting for variable follow-up times and clustering by individual, adjusted for age, race, gentler, and body mass index (BMI) Interaction terms were considered statistically significant at P < 0 10 Results The mean (+/-SD) age of the sample was 61 9 +/- 9.7 yews. the mean BMI was 303 +/- 69 kg/m(2), with 606% women and 424% AA The mean (+/- SD) TGF-beta 1 was 178 +/- 61 ng/ml, follow-up time was 6 1 +/- 1 3 years There were no significant interactions by race or gender HRs showed no significant relationship between lnTGF-beta 1 and incident or progressive rOA, osT, or JSN, at the knee or the hip Conclusions Levels of do not predict incident or progressive rOA, OST, or JSN at the hip or knee in this longitudinal. population-based study. making it unlikely that TGF-beta 1 will be a robust biomarker for rOA in flaw e studies (C) 2010 Osteoarthritis Research Society International Published by Elsevier Ltd All rights reserved